THERAPEUTIC MANAGEMENT OF CYCLOTHYMIA: THE ROLE OF MOOD STABILIZERS AND PSYCHOTHERAPY

Abstract

Cyclothymia is classified as a primary mood disorder within the bipolar spectrum, characterized by chronic affective dysregulation and persistent mood fluctuations. Frequently underdiagnosed due to symptomatic overlap with other psychiatric disorders, this condition represents a clinical challenge that can compromise psychosocial functioning and favor progression to more structured forms of bipolar disorder. This work constitutes a narrative bibliographic analysis, with the purpose of integrating and evaluating contemporary scientific evidence regarding the pharmacological and psychotherapeutic management of cyclothymia, through consultation of the PubMed database. Recent literature demonstrates that, despite the absence of specifically approved therapies, mood stabilizers (Lithium, Valproic Acid, and Lamotrigine) remain the mainstay of pharmacological management, being effective in reducing affective instability. However, management should be integrated, complemented by evidence-based psychotherapeutic interventions such as psychoeducation, cognitive-behavioral therapy, family therapy, and interpersonal and social rhythm therapy. These interventions are fundamental to promoting treatment adherence, early recognition of relapses, and regulation of biological and interpersonal rhythms. Therefore, the treatment of cyclothymia should be conducted through a multidimensional and patient-centered approach.